Application of Methods for Health Technology Assessment

Tuesday June 23, 2015, Allschwil (Basel)

Presentations and Slides

The importance of Health Technology Assessment (HTA) has increased substantially over the last few years. In order to obtain reimbursement, it has become critical for manufacturers to provide additional evidence about their products in a real-world setting to satisfy the requirements of the various national HTA bodies and best guide internal decision-making post market authorization. The Basel Biometric Society (BBS) and the European Federation of Statisticians in the Pharmaceutical Industry (EFSPI) organized a European Scientific Meeting on this relevant topic. The meeting provided a forum to hear about the latest development of methods in the applications of HTA from representatives from European regulatory bodies, and from practitioners in the pharmaceutical industry and academia.

Bridging efficacy to effectiveness: The IMI GetReal project
Health Technology Assessment For Medical Devices
NICE’s approach to the development of guidance for medical devices and diagnostics
EUnetHTA CRC screening full Core Model pilot: reflections on why and how
Gilenya Social Intelligence
Adjusting overall survival for treatment switch
The HTA Core Model : a useful framework for Roche to assess the value of a pharmaceutical product?
Predicting long term survival using non-parametric bayesian methods: the melanoma case
Reimbursement challenges with new emerging cancer therapies
The Value of Oncology Therapies and Emerging Access Hurdles: Canada and the United States